Kinnate Biopharma (KNTE) Stock Forecast & Price Prediction

Estimation of the future price movement of Kinnate Biopharma stock, based on various factors such as historical price trends, market trends, company performance, and economic conditions.

Price target

Current $2.23

Concensus $30.00

Low $30.00

Median $30.00

High $30.00

Based on analysts projections #KNTE is expected to experience a positive growth trajectory over the next year.

The current average KNTE price target, as estimated by these analysts, is $30.00.

The predictions for the future KNTE stock price range from a low of $30.00 to a high of $30.00, highlighting the variability of market expectations for KNTE.

It is important to note that market fluctuations and unforeseen events can have an impact on these projections, so investors should always exercise caution and conduct thorough research before making any investment decisions.

KNTE stock forecasts by analyst

Analyst / firm Date Rating Price target Price when posted
Christopher Raymond
Piper Sandler
May 18, 2022 Buy 30.00 9.96

Kinnate Biopharma (KNTE) Fundamentals Checker

Financial metrics are used to evaluate financial stability which helps analysts determine if Kinnate Biopharma is undervalued compared to its fair value. A company's financial health can strongly influence the stock forecast.


Financial Scores

Updated on: 06/12/2023

Altman Z-Score: -0.4

Piotroski Score: 2.0

ESG Score

Updated on: 06/12/2023

Environmental: 59.9

Social: 58.8

Governance: 60.2

Financial Health

Updated on: 06/12/2023

DCF: Strong Buy

ROE: Strong Sell

ROA: Strong Sell

Debt to equity ratio: Neutral

Price to earnings ratio: Sell

Price to book ratio: Strong Buy

KNTE Discounted Cash Flow

Updated on: 06/12/2023

Discounted Cash Flow Value

Current Price

KNTE Revenues by Segment

Updated on: 06/12/2023

No available data

Revenue from Contract with Customer, Excluding Assessed Tax

KNTE Revenues by Region

Updated on: 06/12/2023

No available data

KNTE Notes Due

Updated on: 06/12/2023


There are no data to display

Kinnate Biopharma (KNTE) Social Sentiments

Monitoring bullish and bearish sentiments towards Kinnate Biopharma on Twitter and Stocktwits could help to forecast an upward or downward trend in Kinnate Biopharma stock price.

Kinnate Biopharma's Stock Forecasts: Precision Medicine Cancer Therapies on the Rise

Kinnate Biopharma (KNTE) is a biotechnology company that focuses on developing cancer treatments by using precision medicine. The company creates therapies for genetically-driven cancers that have limited treatment options. Kinnate Biopharma was founded in 2018 by Dr. Nima Farzan, who serves as the CEO of the company. Dr. Farzan previously worked at Bristol-Myers Squibb and Genentech, where she gained expertise... Read more

Stock Prediction for Kinnate Biopharma: A Promising Investment in Biotechnology

Biotechnology is a field that has been growing rapidly in recent years, and the stock market sector associated with it has seen an interesting evolution. Biotech companies are involved with developing therapies and products based on biological systems, genetics and cellular biology. These companies can be small start-ups or large corporations, but all have one thing in common - to... Read more